S&P 500
5,844.61
-1.6%
-95.85
DJI
41,860.44
-1.9%
-816.80
NASDAQ
$18,872.64
-1.4%
-$270.07
Bitcoin
111,394.00
+3.6%
+3,867.95
AAPL
$202.42
-2.1%
-$4.44
AMZN
$201.35
-1.3%
-$2.72
GOOG
$170.25
+3.0%
+$4.93
META
$635.69
-0.2%
-$1.41
MSFT
$453.22
-1.1%
-$4.95
NVDA
$131.94
-1.8%
-$2.44
TSLA
$334.80
-2.6%
-$9.02
Allena Pharmaceuticals (NASDAQ: ALNA)
Some price data may be temporarily unavailable.
Allena Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Allena Pharmaceuticals Company Info
Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Sudbury, MA.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.